Your search history is turned on.
Date: May 7, 2024 Jurisdictions: British Columbia, Ontario
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: May 7, 2024 Jurisdictions: Alberta, British Columbia, Ontario
FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company BioVaxys Technology Corp. (the Company) 146 Thirtieth Street, Suite 100 Etobicoke, Ontario Canada M8W 3D4 Item 2 Date of Material Change April 30, 2024 Item 3 News Release The Company disseminated a news release announcing the mate...
Date: May 3, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BioVaxys Technology Corp. Closes First Tranche of Private Placement BioVaxys Technology Corp. Closes First Tranche of Private Placement // THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE OR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, May 3, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "Fir...
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, May 2, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the...
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER VANCOUVER, BC, April 30, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has appointed Christopher Cherry as Chief Financial Officer. Mr. Cherry, a Chartered Accountant and Certified Public Accounta...
Date: April 26, 2024 Jurisdictions: Alberta, British Columbia, Ontario
STATEMENT OF EXECUTIVE COMPENSATION DATED: APRIL 26, 2024 1 | P a g e STATEMENT OF EXECUTIVE COMPENSATION Objective: The objective of this disclosure is to communicate the compensation th...
Date: April 18, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, April 18, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, ...
Date: April 10, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY VANCOUVER, BC, and Madison, WI April 10th, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. (SpayVac) jointly ...
Date: April 4, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update VANCOUVER, BC, April 4, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, t...
Date: April 3, 2024 Jurisdictions: Alberta, British Columbia, Ontario
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE VANCOUVER, B.C., April 3, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:...